Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO sells $202,612.98 worth of stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Your Free Report) CMO Joanne M. Donovan sold 7,162 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $28.29, for a total value of $202,612.98. Following the completion of the sale, the chief marketing officer now directly owns 14,538 shares of the company’s stock, valued at approximately $411,280.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink.

Edgewise Therapeutics stock fell 2.2%

Shares of EWTX traded down $0.57 during trading on Tuesday, reaching $25.92. 988,944 shares of the company traded hands, compared to its average volume of 961,431. The stock has a 50-day simple moving average of $19.06 and a 200-day simple moving average of $18.20. The stock has a market cap of $2.42 billion, a PE ratio of -16.72 and a beta of 0.15. Edgewise Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $30.00.

Edgewise Therapeutics (NASDAQ:EWTX – Get Your Free Report ) last issued its earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. On average, equities research analysts predict that Edgewise Therapeutics, Inc. will post -1.48 EPS for the current year.

Hedge funds weigh in on Edgewise Therapeutics

Several hedge funds have recently bought and sold shares of EWTX. Sofinnova Investments Inc. purchased a new position in Edgewise Therapeutics in the second quarter valued at about $8,567,000. Pale Fire Capital SE lifted its position in shares of Edgewise Therapeutics by 529.3% during the fourth quarter. Pale Fire Capital SE now owns 98,449 shares of the company’s stock worth $1,077,000 after acquiring an additional 82,804 shares in the last quarter. Perceptive Advisors LLC purchased a new position in shares of Edgewise Therapeutics in the fourth quarter valued at about $6,078,000. Trexquant Investment LP purchased a new position in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $608,000. Finally, Federated Hermes Inc. purchased a new stake in Edgewise Therapeutics during the second quarter valued at approximately $833,000.

The Wall Street analyst weighs in

Several brokerages have issued reports on EWTX. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Edgewise Therapeutics in a report on Friday, August 16th. Piper Sandler reissued an “overweight” rating and issued a $48.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 1st. Truist Financial lifted their target price on shares of Edgewise Therapeutics from $25.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $32.00 target price on shares of Edgewise Therapeutics in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. upped their target price on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, August 12th. Five analysts have rated the stock with a buy rating. The company presently has an average rating of “Buy” and a consensus price target of $35.00, according to MarketBeat.

See the latest stock report on EWTX

About Edgewise Therapeutics

(Get a free report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule in Phase II clinical trials, is designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy.

Featured stories

Get news and reviews for Edgewise Therapeutics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edgewise Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.